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Abstract
Background: Angiogenesis plays an important role in tumor growth and metastasis, therefore antiangiogenic
therapy was widely investigated as a promising approach for cancer therapy. Recently, pigment epithelium-derived
factor (PEDF) has been shown to be the most potent inhibitor of angiogenesis. Adeno-associated virus (AAV)
vectors have been intensively studied due to their wide tropisms, nonpathogenicity, and long-term transgene
expression in vivo. The objective of this work was to evaluate the ability of AAV-mediated human PEDF (hPEDF) as
a potent tumor suppressor and a potential candidate for cancer gene therapy.
Methods: Recombinant AAV2 encoding hPEDF (rAAV2-hPEDF) was constructed and produced, and then was
assigned for in vitro and in vivo experiments. Conditioned medium from cells infected with rAAV2-hPEDF was used
for cell proliferation and tube formation tests of human umbilical vein endothelial cells (HUVECs). Subsequently,
colorectal peritoneal carcinomatosis (CRPC) mouse model was established and treated with rAAV2-hPEDF.
Therapeutic efficacy of rAAV2-hPEDF were investigated, including tumor growth and metastasis, survival time,
microvessel density (MVD) and apoptosis index of tumor tissues, and hPEDF levels in serum and ascites.
Results: rAAV2-hPEDF was successfully constructed, and transmission electron microscope (TEM) showed that rAAV2-
hPEDF particles were non-enveloped icosahedral shape with a diameter of approximately 20 nm. rAAV2-hPEDF-infected
cells expressed hPEDF protein, and the conditioned medium from infected cells inhibited proliferation and tube-
formation of HUVECs in vitro. Furthermore, in CRPC mouse model, rAAV2-hPEDF significantly suppressed tumor growth
and metastasis, and prolonged survival time of treated mice. Immunofluorescence studies indicated that rAAV2-hPEDF
could inhibit angiogenesis and induce apoptosis in tumor tissues. Besides, hPEDF levels in serum and ascites of rAAV2-
hPEDF-treated mice were significant higher than those in rAAV2-null or normal saline (NS) groups.
Conclusions: Thus, our results suggest that rAAV2-hPEDF may be a potential candidate as an antiangiogenic
therapy agent.
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Background
Cancer is a major public health problem in the world
and causes millions of death each year. More than 1.5
million new cancer cases and 560,000 deaths from can-
cer are projected to occur in 2010 in the USA [1].
Surgical resection, chemotherapy, and radiotherapy are
conventional therapeutic strategies, which were widely
used in clinic. Unfortunately, surgical resection is not
sufficiently effective for advanced cancer, and che-
motherapy and radiotherapy always induce severe side
effects [2,3]. Obviously, it is necessary to develop novel
therapeutic strategies to optimize available non-surgical
approaches. Gene therapy was proposed as a new
approach to eradicate malignant cells, which may be
beneficial to cancer patients at all stages [4].
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dependent on angiogenesis [5]. Tumor less than 1 mm
3
could receive necessary nutrients and oxygen through
diffusion, however, a tumor is unable to grow above
approximate 1 mm
3 without neovascularization [6].
Angiogenesis is a complex multistep process consisting
of proliferation and migration of endothelial cells,
degeneration of basement membrane, and formation of
new lumen, which is tightly regulated by both positive
and negative factors [7]. Microvascularity of normal tis-
sue is regulated by the proangiogenic and antiangiogenic
factors to maintain a quiescent state. Tumor growth and
metastasis require neovascularization, therefore, tumors
use various mechanisms to shift the balance to an
angiogenic inductive environment. In this process, over-
expression of proangiogenic factors is accompanied by
down regulation of antiangiogenic factors [8]. As angio-
genesis is essential for tumor growth and metastasis,
antiangiogenesis has been proposed as a therapeutic
strategy for cancer treatment [9].
Pigment epithelium-derived factor (PEDF), a 50-kDa
secreted glycoprotein, is a member of the serpin super-
family of serine protease inhibitors, which was first iden-
tified in a conditioned medium of cultured primary
human fetal retinal pigment epithelial cells [10]. To
d a t a ,i tw a sf o u n dt h a tP E D Fi sw i d e l ye x p r e s s e di n
human tissues and is involved in many physiological
and pathological processes [11]. PEDF is a multifunc-
tional protein and proved to be neurotrophic, neuropro-
tective, and antiangiogenic. And PEDF has recently been
shown to be a more potent inhibitor of angiogenesis
than other endogenous angiogenic inhibitors, including
angiostatin, endostatin, and thrombospondin-1 [12,13].
Antiangiogenic activity of PEDF was associated with
induction of endothelial cell apoptosis via the Fas/FasL
death pathway and down-regulation of vascular
endothelial growth factor (VEGF) expression. Previous
works suggested that PEDF is a potential tumor sup-
pressor [6,14-17].
Although gene therapy is an effective way to treat can-
cers and many other chronic diseases, the safety and
efficacy of gene therapy depends on the development of
safe and effective delivery systems [18-23]. The recombi-
nant adeno-associated virus (rAAV) vectors appear to be
the promising potential candidate as safe and effective
delivery system for gene therapy due to its attractive fea-
tures [24-27]. rAAV vectors show low immunogenicity
and ability to infect both dividing and nondividing cells.
Besides, rAAV can maintain long-term undiminished
transgene expression in vivo. The most important,
rAAV vectors are nonpathogenic, which are not asso-
ciated with any known human diseases. Until now, sev-
eral different serotypes of AAV have been identified by
serological analysis [28-30], among which rAAV
serotype 2 vectors (rAAV2) are mostly studied and used
in animal experiments and clinical trials [31,32]. Most of
the previous studies about rAAV-mediated gene transfer
of PEDF mainly focused on eye diseases, however,
rAAV-mediated gene transfer of PEDF for tumor treat-
ment is rarely reported.
According to the BLAST analysis, the homology
between human PEDF and mouse PEDF is very high.
Besides, several previous contributions suggested that
hPEDF was effective on mouse tumor models. There-
fore, in this work, we constructed rAAV2 encoding
human PEDF (rAAV2-hPEDF) and investigated its anti-
tumor efficacy in colorectal peritoneal carcinomatosis
(CRPC) mouse model. Our results demonstrated that
rAAV2-hPEDF may be a potent tumor inhibitor and a
potential candidate for cancer gene therapy.
Methods
Cell lines and animals
CT26 cells (murine colon carcinoma cell line) were pur-
chased from the American Type Culture Collection
(ATCC, Rockville, MD) and cultured in RPMI1640 med-
ium (GIBCO, USA) containing 10% fetal bovine serum
(FBS, GIBCO, USA) and 1% penicillin/streptomycin. Pri-
mary HUVECs were isolated from human umbilical
cord veins by a standard procedure [33], and grew in
Dulbecco’s Modified Eagle’sm e d i u m( D M E M ,G I B C O ,
USA) supplemented with 20% fetal bovine serum (FBS,
GIBCO, USA)and basic fibroblast growth factor (bFGF,
10 ng/ml). HUVECs at passages 2 to 3 were used for
experiments. All above cells were maintained at 37°°C in
a humidified incubator containing 5% CO2.
BALB/c mice weighing 20 to 22 g were purchased
from the Laboratory Animal Center of Sichuan Univer-
s i t ya n dh o u s e da tc o n t r o l l e dt e m p e r a t u r eo f2 0 - 2 2 ° ° C ,
relative humidity of 50-60% and 12 h light-dark cycles.
Animals were provided with standard laboratory chow
and tap water ad libitum. All the animals would be in
quarantine for a week before treatment. All animal pro-
cedures were performed following the protocol approved
by the Institutional Animal Care and Treatment Com-
mittee of Sichuan University (Chengdu, P.R. China). All
mice were treated humanely throughout the experimen-
tal period.
rAAV vector construction and production
According to standard cloning techniques, the human
PEDF (hPEDF) cDNA was amplified from pBLAST49-
hPEDF template (stored by State Key Laboratory of
Biotherapy, West China Hospital, Sichuan University,
Chengdu, China) using the designed primers (the
upstream primer: 5’-GGAATTCATGCAGGCCCT
GGTGCTACTC-3’; the downstream primer: 5’-
ACGCGTCGACTTAGGGGCCCCTGGGGTC-3’), and
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by Dr. Wu XB, State Key Laboratory for Molecular Vir-
ology and Genetic Engineering, Beijing, China) to form
the new plasmid, pAAV2-hPEDF (Figure 1A). The con-
trol plasmid pAAV2-null was constructed in the similar
manner (Figure 1A). Packaging and purification of
rAAV particles were done as descried previously [34].
The morphological characteristics of rAAV2-hPEDF par-
ticles were examined by transmission electron micro-
scope (TEM, H-6009IV, Hitachi, Tokyo, Japan). The
titers of rAAV2-hPEDF and rAAV2-null measured by
dot blot DNA analysis were 4 × 10
12 v.g./mL and 1 ×
10
12 v.g./mL, respectively. All viruses prepared in this
study were stored at 4°°C in PBS before use.
rAAV2-hPEDF infection assay
Approximately 2 × 10
5 CT26 cells were plated into 6-
well plates in complete medium and allowed to attach
for 24 hours. Subsequently, cells were gently washed
with PBS, and then rAAV2-hPEDF or rAAV2-null was
applied to cells at MOI (multiplicity of infection) of 10
5
v.g. per cell in serum-free medium, with normal saline
(NS) as non-infection control. After incubation for 6
hours, complete medium with 10% FBS was added to
each well. Then, the conditioned medium was collected
after further culture for 72 hours for western blotting
analysis and cell proliferation assay.
Western blotting analysis
Conditioned media from CT26 cells infected with
rAAV2-hPEDF, rAAV2-null or NS were used for Wes-
tern blotting analysis. Concentrations of protein were
determined using a modified Lowry protein assay kit
(ThermoScientific), and an equal amount of protein (40
μg) from each sample was loaded on to 10% SDS-PAGE
gel followed by transfer to a nitrocellulose membrane
sheet, probed for anti-PEDF (1:500, upstates, Lake Pla-
cid, USA). The membranes were washed, and blots were
developed with horseradish peroxidase (HRP)-conju-
gated secondary antibodies. The protein bands were
detected using an enhanced chemiluminescence (ECL)
detection system. (Pierce, Rockford, Illinois, USA).
Cell proliferation assay
Cell proliferation assay wasc o n d u c t e du s i n g3 - ( 4 , 5 -
dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bro-
mide (methyl thiazolyl tetrazolium, MTT) method to
determine the effect of hPEDF derived from rAAV2-
hPEDF infected cells on HUVECs. HUVECs were plated
at a density of 1 × 10
4 cells per well in 100 μLo fm e d -
ium in 96-well plates and grown for 48 hours. The con-
ditioned media from CT26 cells infected with rAAV2-
hPEDF, rAAV2-null, or NS were collected as described
above, and each supernatant was two-fold serially
diluted and added to each well in triplicate. After 48
hours of incubation, viability of cells was measured
using MTT method. The mean percentage of cell survi-
val relative to that of untreated cells was estimated from
data from three individual experiments, and all data
were expressed as the mean value ± standard deviation
(S.D.).
Endothelial cell capillary-like tube formation assay
Tube formation assay was conducted as previously
described [35]. Briefly, prechilled Matrigel was pipetted
into prechilled 24-well plates and polymerized at 37°°C
for 30 minutes. Then, HUVECs suspended in complete
medium were seeded onto the Matrigel, and they were
treated with conditioned medium form cells infected
with NS, rAAV2-null, or rAAV2-hPEDF, respectively.
After 6 hours of incubation, the endothelial cells were
photographed with a digital camera attached to an
inverted microscope. Three independent experiments
were performed.
Animal model and treat plan
CRPC mouse model was established and subsequently
treated. Briefly, the mice were intraperitoneally injected
with 200 μl of cell suspension containing 5 × 10
5 CT26
cells. Tumors were allowed to grow for 3 days. Tumor-
b e a r i n gm i c ew e r er a n d o m l ya s s i g n e dt oo n eo ft h ef o l -
lowing groups (n = 12 mice per group): NS, rAAV2-null
(2 × 10
10 v.g. per mouse), and rAAV2-hPEDF (2 × 10
10
v.g. per mouse).
Treatments were administered through intraperitoneal
injection with a single dose of 200 μl above mentioned
viruses. For tumor growth inhibition study (6 mice per
group), the number and weight of tumor nodes in each
group were measured on day 18 after tumor cell
Figure 1 Construction scheme and characterization of rAAV2-
hPEDF. A: Construction scheme of rAAV2-hPEDF and control vector
rAAV2-null; B: TEM image of rAAV2-hPEDF particles; C: Expression of
hPEDF in rAAV2-hPEDF infected CT26 cells.
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mice began to die. To further study the therapeutic
effect against colorectal cancer, the survival time of
mice treated with the protocols described above was
observed (6 mice per group).
Detection of microvessel density (MVD)
The antiangiogenesis of rAAV2-hPEDF was determined
by immunofluorescent analysis of neovascularization in
tumor tissue as described [36]. Briefly, frozen sections of
tumors were fixed in acetone, washed with PBS, stained
with rat anti-mouse CD31 (platelet endothelial cell
adhesion molecule-1) polyclonal antibody (1:50; BD
Pharmingen™, USA), washed twice with PBS, and fol-
lowed by incubation with a Rhodamine-conjugated sec-
ond antibody (Abcam, USA). MVD was determined by
counting the number of microvessels per high-power
field in the sections with a fluorescence microscopy as
described.
Quantitative assessment of apoptosis
Tumor sections were prepared as described above.
Terminal deoxynucleotidyl transferase-mediated nick-
end labeling (TUNEL) staining was done using an in
situ cell death detection kit (DeadEnd™ Fluorometric
TUNEL System, Promega, Madison, USA) following the
manufacturer’s protocol. It is based on the enzymatic
addition of digoxigenin-nucleotide to the nicked DNA
by the recombinant terminal deoxynucleotidyl transfer-
ase (rTdT) [37]. In the tissue sections, four equal-sized
fields were randomly chosen and analyzed. The apopto-
tic index was calculated as a ratio of the apoptotic cell
number to the total tumor cell number in each high-
power field.
Detection of hPEDF concentrations in serum and ascites
Quantitation of hPEDF expression in serum and ascites
was determined by enzyme-linked immunosorbnent assay
(ELISA). A commercial PEDF ELISA kit (ADL, Biotech.
Dev. Co., USA) was used following the manufacturer’s
instructions. Briefly, pre-diluted serum or ascites were
added to wells of the pre-coated ELISA plate and incu-
bated for one hour. After washing, HRP-conjugated sec-
ondary antibody was added. Antibody binding was
detected with substrate A and B. After the reaction was
stopped with H2SO4, the absorbance at 450 nm was mea-
sured by an ELISA reader (Bio-Rad 680, USA).
Toxicity evaluation
To investigate potential toxicity or side effects of
rAAV2-hPEDF, mice were observed continuously during
the treatment process, including the general conditions
(the activity, energy, hair, feces, behavior pattern, and
other clinical signs), body weight, and mortality. For
histopathological studies, samples were obtained from
major organs including heart, liver, spleen, lungs, and
kidneys. All the samples were fixed in 10% neutral-buf-
fered formalin, and embedded in paraffin. Then, the tis-
sues were sectioned and stained with hematoxylin and
eosin (H&E).
Statistical analysis
The statistic analysis was carried out using SPSS 15.0
software (Chicago, IL, USA). Comparison of numbers of
tumor nodes was performed using one-way analysis of
variance (ANOVA). Survival curves were generated
based on the Kaplan-Meier method and statistical signif-
icance was determined by Mann-Whitney U-tests. A P
value < 0.05 on a 2-tailed test was considered statisti-
cally significant.
Results
Expression of hPEDF in colonic cancer cells after rAAV-
mediated gene transfer in vitro
rAAV2-hPEDF was successfully constructed (Figure 1A).
TEM was used to determine the morphological charac-
teristics of rAAV2-hPEDF particles. As presented in Fig-
ure 1B, rAAV2-hPEDF particles were non-enveloped
icosahedral shape with a diameter of approximately 20
nm. To determine whether hPEDF could be secreted by
rAAV2-hPEDF-infected cells, we analyzed the condi-
tioned medium from CT26 cells infected in vitro with
either rAAV2-hPEDF or control vector rAAV2-null by
Western blotting analysis using a monoclonal antibody
against hPEDF. As shown in Figure 1C, in the condi-
tioned medium from rAAV2-hPEDF-infected cells, only
one band with molecular weight of 50 kDa was
observed, which coincided with the lane loaded with
hPEDF protein. There was no hPEDF expression in the
conditioned medium from the cells infected with control
vector rAAV2-null or NS control. This result suggested
that rAAV2-hPEDF could transfer hPEDF gene into cul-
tured cells and produce secretory protein.
Biological activity of hPEDF produced by rAAV2-hPEDF in
vitro
To evaluate the bioactivity of secreted hPEDF from
CT26 cells infected with rAAV2-hPEDF, HUVEC prolif-
eration assay and endothelial cell capillary-like tube for-
mation assay were conducted.
For in vitro HUVEC proliferation assay, HUVECs were
exposed to the conditioned media from CT26 cells
infected with rAAV2-hPEDF, rAAV2-null, or NS, respec-
tively. After 48 hours of incubation, viability of HUVECs
was measured using MTT method. We found that incu-
bation with the conditioned medium from CT26 cells
infected with rAAV2-hPEDF significantly inhibited
HUVEC proliferation compared with the conditioned
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According to Figure 2, the conditioned medium from
cells infected with rAAV2-hPEDF inhibited HUVEC pro-
liferation by 59.9 ± 8.1% at a 1:2 dilution concentration,
and the inhibitory rate decrease with the increase of
dilution concentration showing a dose-dependent effect.
In contrast, the conditioned medium from rAAV2-null
had no inhibitory effect on the proliferation of HUVECs.
Although angiogenesis is a complex process of several
kinds of cells, tube formation of endothelial cells is one
of the key steps of angiogenesis. Two-dimensional
Matrigel assay was used to examine the potential effects
of conditioned media from cells infected with rAAV2-
hPEDF, rAAV2-null, or NS on the capillary-like struc-
ture formation of endothelial cells, respectively. As
shown in Figure 3, HUVECs seeded on the surface of
Matrigel formed capillary-like structures in conditioned
medium from NS or rAAV2-null group within 6 hours.
However, treatment with the conditioned medium from
cells infected with rAAV2-hPEDF strongly reduced the
tube formation of endothelial cells (Figure 3D).
These results indicated that the hPEDF secreted by
infected cells was highly bioactive and could block
angiogenesis in vitro by inhibiting the proliferation and
reducing the formation of tube-like structure of
endothelial cells.
Inhibition of tumor growth and metastasis with rAAV2-
hPEDF
To investigate the therapeutic effect of rAAV2-hPEDF,
forty-eight CRPC mice were divided into three groups
and treated with NS, rAAV2-null, or rAAV2-hPEDF,
respectively. On day 18 after cell inoculation, mean
number and weight of tumor nodes in rAAV2-hPEDF-
treated group were dramatically decreased compared
with those in rAAV2-null (P < 0.001 and P < 0.001,
respectively) or NS group (P <0 . 0 0 1a n dP <0 . 0 0 1 ,
respectively) (Figure 4A and 4B). Besides, the size of
tumor nodes in rAAV2-hPEDF-treated group was signif-
icantly smaller in comparison with control groups (Fig-
ure 4A). According to H&E staining of tumor in each
group, less vessels and remarkable necrosis areas were
observed in tumor tissues from rAAV2-hPEDF group
(Figure 4A). These findings indicated rAAV2-hPEDF not
only inhibits growth of implanted tumor, but also
impairs tumor metastasis. Furthermore, there was a sub-
stantial increase in the life span of the rAAV2-hPEDF-
treated mice, and the median survival of rAAV2-hPEDF
group was 37 days versus 24 days or 25 days in rAAV2-
null or NS group, respectively (Figure 4C). Besides, due
to the inhibition of tumor growth and metastasis, body
weight of mice in rAAV2-hPEDF-treated group
increased slower compared with that in NS or rAAV2-
null groups (Figure 4D). Mice were investigated in parti-
cular for potential side effects attributable to rAAV2-
hPEDF therapy. No severe toxic effects were observed in
gross measures, such as severe weight loss, changes in
behavior, and feeding. Moreover, no histopathological
changes were found in major organs including heart,
liver, spleen, lungs, and kidneys (Figure 4E).
Inhibition of tumor angiogenesis
To better understand the mechanism by which treat-
ment with rAAV2-hPEDF inhibited the tumor growth
Figure 2 Inhibitory effect of rAAV2-hPEDF on proliferation of
HUVECs in vitro. Exponentially growing HUVECs were exposed to
the conditioned medium from rAAV2-hPEDF, rAAV2-null, or NS
infected CT26 cells for 72 hours. Percent inhibition was calculated
by the MTT method. Columns, mean of three independent
experiments; error bars, SD.
Figure 3 rAAV2-hPEDF inhibited tube formation of HUVECs.
Representative photographs of HUVECs treated with the
conditioned medium from NS (A), rAAV2-null (B), or rAAV2-hPEDF (C)
infected CT26 cells, and inhibition ratio of tube formation (D).
Columns, mean of three independent experiments; error bars, SD.
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Sections of tumor nodes from mice in all three treat-
ment groups were stained for CD31 immunofluores-
cence to determine the MVD as a measure of tumor
angiogenesis (Figure 5). As shown in Figure 5A to 5C,
significant fewer immunoreactive microvessels were
observed in tumor tissue from mice treated with
rAAV2-hPEDF. According to Figure 5D, MVD of tumor
tissues from rAAV2-hPEDF-treated mice (18.6 ± 4.7)
was significant lower compared with control vessel
rAAV2-null (49.6 ± 7.7, p < 0.001) or NS group (49.0 ±
8.7, p < 0.001).
Induction of tumor apoptosis
To explore the role of rAAV2-hPEDF on apoptosis of
tumor cells, tumor resections were subjected to immu-
nofluorescent TUNEL staining assays for respective
determination of apoptotic index. As shown in Figure
6A to 6C, within a similar high-power field, more
apoptotic cells (with green nuclei) in tumor tissues
were observed in rAAV2-hPEDF-treated mice com-
pared with those in rAAV2-null or NS group. The
apoptosis index was significantly higher in rAAV2-
hPEDF group (28.6% ± 5.0%) than in rAAV2-null (7.4%
±2 . 9 % ,p < 0.001) or NS group (4.4% ± 1.5%, p <
0.001), respectively (Figure 6D).
hPEDF concentrations in serum and ascites
To evaluate whether the suppression of tumor growth
and metastasis and increase of life span in rAAV2-
hPEDF-treated group is associated with the hPEDF
expression, hPEDF concentrations in serum and ascites
were measured in each treatment groups. Data in Figure
7 show the hPEDF levels in serum and ascites on day 18
after tumor cell inoculation. hPEDF levels in serum
(21.87 ± 5.94 ng/mL) or ascites (42.23 ± 6.80 ng/mL) in
rAAV2-hPEDF-treated group were significantly higher
than those in rAAV2-null (3.03 ± 1.61 ng/mL in serum,
Figure 4 rAAV2-hPEDF inhibited growth and metastasis in
CRPC model, and prolonged survival time of treated mice.A :
Representative photographs and H&E staining of abdominal tumors
in NS (a), rAAV2-null (b), and rAAV2-hPEDF (c) groups; B: Mean
number and weight of tumor nodules in each group; C: Survival
curves of mice in each group; D: Body weight of mice in each
group; E: Photographs of major organs after intraperitoneal
administration of rAAV2-hPEDF and NS (×400).
Figure 5 CD31 immunofluorescent staining of tumor nodules.
Representative CD31 immunofluorescent images of NS (A), rAAV2-
null (B), and rAAV2-hPEDF (C) group, and mean MVD in each group.
Figure 6 TUNEL immunofluorescent staining of tumor nodules.
Representative TUNEL immunofluorescent images of NS (A), rAAV2-
null (B), and rAAV2-hPEDF (C) group, and mean apoptotic index in
each group.
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NS (3.83 ± 1.76 ng/mL in serum, P < 0.001; 3.57 ± 1.47
ng/mL in ascites, P < 0.001) group, respectively.
Furthermore, in rAAV2-hPEDF-treated group, hPEDF
level in ascites was significantly higher than that in
serum (P < 0.001). The results indicated that intraperito-
neal injection of rAAV2-hPEDF produced high level
secretory hPEDF protein in mice, which inhibited the
growth and metastasis of tumor.
Discussion
Colorectal carcinoma is one of the most frequent can-
cers, and is the third leading cause of cancer-associated
deaths worldwide [7]. Besides liver metastasis and regio-
nal lymph nodes metastasis, peritoneal carcinomatosis
of colon cancer occurs in 12-20% of patients whose dis-
ease recurs [38,39]. However, therapeutic effects of con-
ventional treatments, such as surgical resection,
chemotherapy and radiotherapy, are not very encoura-
ging. Therefore, unremitting efforts were focused on
developing novel therapeutic strategies. Data presented
in this study showed that AAV-mediated delivery of
hPEDF could prevent tumor growth and metastasis and
prolong the survival time in murine CRPC model (Fig-
ure 4A to 4D).
Angiogenesis is essential to maintain tumor growth
and metastasis, therefore antiangiogenic therapy is a fea-
sible approach for cancer therapy. In recent years, a
variety of angiogenesis inhibitors have been discovered,
among which PEDF is the most promising one. Based
on previous studies, down-regulation of PEDF e was
very prevalent in a range of tumors [11]. There are two
major pathways by which PEDF exerts its antitumor
effects: antiangiogenesis and apoptosis-mediated tumor
suppression. In this study, we examined biological activ-
ity of hPEDF produced by rAAV2-hPEDF in vitro and in
vivo. In HUVEC proliferation assay, the conditioned
medium from cells infected with rAAV2-hPEDF inhib-
ited HUVEC proliferation by 59.9 ± 8.1% at a 1:2 dilu-
tion concentration (Figure 2). In HUVEC tube
formation assay, treatment with the conditioned med-
ium from cells infected with rAAV2-hPEDF dramatically
reduced the tube formation of HUVECs by 85.8% ±
4.7% (Figure 3). Furthermore, sections of tumors stained
for CD31 immunofluorescence showed that the MVD of
tumors in rAAV2-hPEDF-treated mice was reduced by
62.1 ± 9.6% compared with control group. In immuno-
fluorescent TUNEL staining assay, the apoptosis index
in rAAV2-hPEDF group increased by 6.5 times com-
pared with NS group (Figure 6). Therefore, our in vitro
and in vivo results suggested that suppression of tumor
growth and metastasis by rAAV2-hPEDF was associated
with the decreased MVD and induction of apoptosis in
tumors.
Antiangiogenic therapy requires constant therapeutic
levels of antiangiogenic factors in vivo to achieve its
therapeutic effect, therefore recombinant proteins are
limited for widespread clinical use [40]. It is because
high therapeutic doses of recombinant proteins are
needed, but resultant yield rates of recombinant proteins
may be low due to denaturizing in purification process.
Furthermore, owing to the short half-life of protein in
vivo, maintaining therapeutically effective serum levels
needs a frequent dosing regimen and high doses of
expensive purified recombinant proteins. Thus, efforts
should be made to develop effective and wide-applied
strategy, and one potential solution for this is gene ther-
apy. The key of successful gene therapy is gene delivery
system. AAV, as one of the most promising viral vectors
for human gene therapy, has many advantages compared
to other viral vectors, such as non-pathogenicity, low
immunogenicity, and long-term undiminished transgene
expression in vivo. Since the first infectious clone of
AAV2 was established in 1982, AAV2 vectors have
gained increasing attention in gene therapy applications
[41,42]. AAV2 have been extensively investigated in pre-
clinical studies for many diseases, including hemophilia,
rheumatoid arthritis, cystic fibrosis, and etc [42,43].
However, further studies suggested that most humans
exposed to AAV2 would develop neutralizing antibodies
to the vector, which hindered its transduction efficiency
[44,45]. Although the application of AAV2 hampers clin-
ical potential of this approach, the use of well-studied
AAV2 will provide preliminary proof of efficacy which
would warrant future studies using vectors derived from
other serotypes. In this study, we successfully con-
structed and produced rAAV2-hPEDF, and the titer of
rAAV2-hPEDF was 4 × 10
12 v.g./mL. Besides, the
Figure 7 hPEDF concentrations in serum and ascites at day 18
after tumor inoculation. hPEDF levels in serum and ascites of
rAAV2-hPEDF-treated mice were significant higher than those in
rAAV2-null (P < 0.001) or NS (P < 0.001) groups.
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Page 7 of 9morphological characteristics of rAAV2-hPEDF were
detected by TEM, which exhibited that rAAV2-hPEDF
particles were non-enveloped icosahedral shape with a
diameter of approximately 20 nm (Figure 1B). A single
intraperitoneal administration of rAAV2-hPEDF resulted
in suppression of tumor growth and metastasis in the
CRPC mouse model with maximum inhibition of
75.85% (Figure 4B). Besides, our results indicated that a
single intraperitoneal administration of rAAV2-hPEDF
could increase hPEDF levels in serum and ascites for a
long period (Figure 7), which could continue to inhibit
angiogenesis in tumor. During the treatment process, no
severe toxic effects were observed, and no histopatholo-
gical changes were found in major organs (Figure 4E).
All these data confirmed that AAV is a safe and efficient
gene delivery vector.
Conclusions
In conclusion, our studies demonstrated that rAAV2-
hPEDF could infect cells and produce secretory hPEDF
protein, which was proved to be functional on inhibiting
proliferation and tube-formation of HUVECs in vitro.
Moreover, rAAV2-hPEDF significantly suppressed tumor
growth and metastasis and prolonged survival time of
treated mice in CRPC model. rAAV2-hPEDF could
increase hPEDF levels in serum and ascites, inhibit
angiogenesis, and induce apoptosis in tumor tissues.
Therefore, our results indicated that rAAV2-hPEDF may
be a potential candidate as an antiangiogenesis therapy
agent for cancer gene therapy.
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